Loading...

Purified anti-mouse NK-1.1 Antibody Purified anti-mouse NK-1.1 Antibody

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136_Purified_NK-11_Antibody_051018
C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and purified NK1.1 (clone PK136) (left) or purified mouse IgG2a, κ isotype control (right), followed by anti-mouse IgG2a PE.
  • PK136_Purified_NK-11_Antibody_051018
    C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and purified NK1.1 (clone PK136) (left) or purified mouse IgG2a, κ isotype control (right), followed by anti-mouse IgG2a PE.
Compare all formats
Cat # Size Price Quantity Check Availability Save
108702 500 µg NOK1238
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108701 50 µg NOK248
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
IP, Deplete, Block, IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  2. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  3. Tersteegen A, et al. 2021. Infect Immun. 89:. PubMed
  4. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  5. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  6. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  7. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  8. Brassington K, et al. 2022. Front Immunol. 13:1040233. PubMed
  9. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  10. Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed
  11. Yun IS, et al. 2019. Yonsei Med J. 60:854. PubMed
  12. Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed
  13. Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed
  14. Goel S, et al. 2017. Nature. 548:471. PubMed
  15. Kim J, et al. 2009. Exp Mol Med. 30:288. PubMed
  16. Lee H, et al. 2014. Invest Ophthalmol Vis Sci . 55:2885. PubMed
  17. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  18. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  19. Kitai Y, et al. 2017. J Immunol. 198:1649. PubMed
  20. Lee JH, et al. 2022. iScience. 25:104166. PubMed
  21. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  22. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  23. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  24. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  25. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  26. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  27. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  28. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  29. Hiratsuka S, et al. 2018. EMBO Mol Med. 10:e8643. PubMed
  30. Hosomi S, et al. 2017. J Exp Med. 214:2985. PubMed
  31. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  32. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  33. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  34. He LD, et al. 2021. EMBO Rep. 22:e52196. PubMed
  35. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  36. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  37. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  38. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  39. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  40. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  41. Zhong X, et al. 2020. Proc Natl Acad Sci U S A. 8563:117. PubMed
  42. Simonović N, et al. 2019. J Immunol. 202:1724. PubMed
  43. Du J, et al. 2018. AMB Express. 8:158. PubMed
  44. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  45. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  46. Jang SC, et al. 2021. Commun Biol. 4:497. PubMed
  47. You X, et al. 2022. Front Genet. 12:790990. PubMed
  48. Renand A, et al. 2018. J Allergy Clin Immunol. 141:1750. PubMed
  49. Sanmarco LM, et al. 2021. Nature. 590:473. PubMed
  50. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  51. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  52. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  53. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  54. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  55. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  56. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  57. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  58. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  59. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  60. Aguilar OA, et al. 2020. J Immunol. 205:1709. PubMed
  61. Liu Q, et al. 2022. Front Immunol. 13:875718. PubMed
  62. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed
  64. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  65. Yamamoto K, et al. 2022. STAR Protoc. 3:101155. PubMed
  66. Yamamoto K, et al. 2021. iScience. 24:103064. PubMed
  67. Silva-Cayetano A, et al. 2020. Med. 2(3):243-262.e8. PubMed
  68. Li ZY, et al. 2021. J Exp Med. 218:. PubMed
  69. Gui J, et al. 2007. Int Immunol. 1.625694444. PubMed
  70. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  71. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
  72. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  73. Jacobs L, et al. 2022. Cancer Gene Ther. 29:984. PubMed
  74. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  75. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  76. Tersteegen A, et al. 2021. Infect Immun. 89:. PubMed
  77. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  78. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  79. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  80. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  81. Brassington K, et al. 2022. Front Immunol. 13:1040233. PubMed
  82. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  83. Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed
  84. Yun IS, et al. 2019. Yonsei Med J. 60:854. PubMed
  85. Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed
  86. Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed
  87. Goel S, et al. 2017. Nature. 548:471. PubMed
  88. Kim J, et al. 2009. Exp Mol Med. 30:288. PubMed
  89. Lee H, et al. 2014. Invest Ophthalmol Vis Sci . 55:2885. PubMed
  90. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  91. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  92. Kitai Y, et al. 2017. J Immunol. 198:1649. PubMed
  93. Lee JH, et al. 2022. iScience. 25:104166. PubMed
  94. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  95. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  96. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  97. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  98. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  99. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  100. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  101. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  102. Hiratsuka S, et al. 2018. EMBO Mol Med. 10:e8643. PubMed
  103. Hosomi S, et al. 2017. J Exp Med. 214:2985. PubMed
  104. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  105. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  106. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  107. He LD, et al. 2021. EMBO Rep. 22:e52196. PubMed
  108. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  109. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  110. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  111. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  112. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  113. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  114. Zhong X, et al. 2020. Proc Natl Acad Sci U S A. 8563:117. PubMed
  115. Simonović N, et al. 2019. J Immunol. 202:1724. PubMed
  116. Du J, et al. 2018. AMB Express. 8:158. PubMed
  117. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  118. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  119. Jang SC, et al. 2021. Commun Biol. 4:497. PubMed
  120. You X, et al. 2022. Front Genet. 12:790990. PubMed
  121. Renand A, et al. 2018. J Allergy Clin Immunol. 141:1750. PubMed
  122. Sanmarco LM, et al. 2021. Nature. 590:473. PubMed
  123. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  124. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  125. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  126. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  127. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  128. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  129. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  130. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  131. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  132. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  133. Aguilar OA, et al. 2020. J Immunol. 205:1709. PubMed
  134. Liu Q, et al. 2022. Front Immunol. 13:875718. PubMed
  135. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  136. Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed
  137. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  138. Yamamoto K, et al. 2022. STAR Protoc. 3:101155. PubMed
  139. Yamamoto K, et al. 2021. iScience. 24:103064. PubMed
  140. Silva-Cayetano A, et al. 2020. Med. 2(3):243-262.e8. PubMed
  141. Li ZY, et al. 2021. J Exp Med. 218:. PubMed
  142. Gui J, et al. 2007. Int Immunol. 1.625694444. PubMed
  143. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  144. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
  145. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  146. Jacobs L, et al. 2022. Cancer Gene Ther. 29:984. PubMed
RRID
AB_313389 (BioLegend Cat. No. 108702)
AB_313388 (BioLegend Cat. No. 108701)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Spark YG™ 593 anti-mouse NK-1.1 (Flexi-Fluor™) Antibody PK136 FC
Go To Top Version: 3    Revision Date: 05.10.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136_Purified_NK-11_Antibody_051018
C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and purified NK1.1 (clone PK136) (left) or purified mouse IgG2a, κ isotype control (right), followed by anti-mouse IgG2a PE.
  • PK136_Purified_NK-11_Antibody_051018
    C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and purified NK1.1 (clone PK136) (left) or purified mouse IgG2a, κ isotype control (right), followed by anti-mouse IgG2a PE.
Compare all formats
Cat # Size Price Quantity Check Availability Save
108702 500 µg NOK1238
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108701 50 µg NOK248
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
IP, Deplete, Block, IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  2. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  3. Tersteegen A, et al. 2021. Infect Immun. 89:. PubMed
  4. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  5. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  6. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  7. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  8. Brassington K, et al. 2022. Front Immunol. 13:1040233. PubMed
  9. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  10. Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed
  11. Yun IS, et al. 2019. Yonsei Med J. 60:854. PubMed
  12. Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed
  13. Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed
  14. Goel S, et al. 2017. Nature. 548:471. PubMed
  15. Kim J, et al. 2009. Exp Mol Med. 30:288. PubMed
  16. Lee H, et al. 2014. Invest Ophthalmol Vis Sci . 55:2885. PubMed
  17. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  18. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  19. Kitai Y, et al. 2017. J Immunol. 198:1649. PubMed
  20. Lee JH, et al. 2022. iScience. 25:104166. PubMed
  21. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  22. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  23. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  24. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  25. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  26. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  27. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  28. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  29. Hiratsuka S, et al. 2018. EMBO Mol Med. 10:e8643. PubMed
  30. Hosomi S, et al. 2017. J Exp Med. 214:2985. PubMed
  31. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  32. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  33. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  34. He LD, et al. 2021. EMBO Rep. 22:e52196. PubMed
  35. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  36. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  37. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  38. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  39. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  40. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  41. Zhong X, et al. 2020. Proc Natl Acad Sci U S A. 8563:117. PubMed
  42. Simonović N, et al. 2019. J Immunol. 202:1724. PubMed
  43. Du J, et al. 2018. AMB Express. 8:158. PubMed
  44. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  45. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  46. Jang SC, et al. 2021. Commun Biol. 4:497. PubMed
  47. You X, et al. 2022. Front Genet. 12:790990. PubMed
  48. Renand A, et al. 2018. J Allergy Clin Immunol. 141:1750. PubMed
  49. Sanmarco LM, et al. 2021. Nature. 590:473. PubMed
  50. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  51. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  52. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  53. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  54. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  55. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  56. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  57. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  58. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  59. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  60. Aguilar OA, et al. 2020. J Immunol. 205:1709. PubMed
  61. Liu Q, et al. 2022. Front Immunol. 13:875718. PubMed
  62. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed
  64. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  65. Yamamoto K, et al. 2022. STAR Protoc. 3:101155. PubMed
  66. Yamamoto K, et al. 2021. iScience. 24:103064. PubMed
  67. Silva-Cayetano A, et al. 2020. Med. 2(3):243-262.e8. PubMed
  68. Li ZY, et al. 2021. J Exp Med. 218:. PubMed
  69. Gui J, et al. 2007. Int Immunol. 1.625694444. PubMed
  70. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  71. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
  72. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  73. Jacobs L, et al. 2022. Cancer Gene Ther. 29:984. PubMed
  74. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  75. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  76. Tersteegen A, et al. 2021. Infect Immun. 89:. PubMed
  77. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  78. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  79. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  80. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  81. Brassington K, et al. 2022. Front Immunol. 13:1040233. PubMed
  82. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  83. Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed
  84. Yun IS, et al. 2019. Yonsei Med J. 60:854. PubMed
  85. Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed
  86. Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed
  87. Goel S, et al. 2017. Nature. 548:471. PubMed
  88. Kim J, et al. 2009. Exp Mol Med. 30:288. PubMed
  89. Lee H, et al. 2014. Invest Ophthalmol Vis Sci . 55:2885. PubMed
  90. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  91. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  92. Kitai Y, et al. 2017. J Immunol. 198:1649. PubMed
  93. Lee JH, et al. 2022. iScience. 25:104166. PubMed
  94. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  95. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  96. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  97. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  98. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  99. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  100. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  101. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  102. Hiratsuka S, et al. 2018. EMBO Mol Med. 10:e8643. PubMed
  103. Hosomi S, et al. 2017. J Exp Med. 214:2985. PubMed
  104. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  105. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  106. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  107. He LD, et al. 2021. EMBO Rep. 22:e52196. PubMed
  108. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  109. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  110. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  111. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  112. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  113. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  114. Zhong X, et al. 2020. Proc Natl Acad Sci U S A. 8563:117. PubMed
  115. Simonović N, et al. 2019. J Immunol. 202:1724. PubMed
  116. Du J, et al. 2018. AMB Express. 8:158. PubMed
  117. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  118. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  119. Jang SC, et al. 2021. Commun Biol. 4:497. PubMed
  120. You X, et al. 2022. Front Genet. 12:790990. PubMed
  121. Renand A, et al. 2018. J Allergy Clin Immunol. 141:1750. PubMed
  122. Sanmarco LM, et al. 2021. Nature. 590:473. PubMed
  123. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  124. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  125. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  126. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  127. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  128. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  129. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  130. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  131. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  132. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  133. Aguilar OA, et al. 2020. J Immunol. 205:1709. PubMed
  134. Liu Q, et al. 2022. Front Immunol. 13:875718. PubMed
  135. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  136. Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed
  137. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  138. Yamamoto K, et al. 2022. STAR Protoc. 3:101155. PubMed
  139. Yamamoto K, et al. 2021. iScience. 24:103064. PubMed
  140. Silva-Cayetano A, et al. 2020. Med. 2(3):243-262.e8. PubMed
  141. Li ZY, et al. 2021. J Exp Med. 218:. PubMed
  142. Gui J, et al. 2007. Int Immunol. 1.625694444. PubMed
  143. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  144. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
  145. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  146. Jacobs L, et al. 2022. Cancer Gene Ther. 29:984. PubMed
RRID
AB_313389 (BioLegend Cat. No. 108702)
AB_313388 (BioLegend Cat. No. 108701)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Spark YG™ 593 anti-mouse NK-1.1 (Flexi-Fluor™) Antibody PK136 FC
Go To Top Version: 3    Revision Date: 05.10.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account